1,101
Views
30
CrossRef citations to date
0
Altmetric
Drug Profile

Pembrolizumab for the treatment of non-small cell lung cancer

, , &
Pages 399-409 | Received 23 Jan 2017, Accepted 23 Mar 2017, Published online: 03 Apr 2017

References

  • Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: off J Eur Soc Med Oncol. 2016;27:v1–v27. Epub 2016/09/25
  • Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: off J Eur Soc Med Oncol. 2014;25Suppl 3:iii27–39. Epub 2014/08/15
  • Zago G, Muller M, van den Heuvel M, et al. New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics: Targets Ther. 2016;10:103–117.
  • DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271.
  • Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, Version 4.2016. J Natl Compr Cancer Network: JNCCN. 2016;14:255–264. Epub 2016/03/10
  • Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol: off J Eur Soc Med Oncol. 2014;25:1681–1690.
  • Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–567. Epub 2003/04/22
  • Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–12297.
  • Strome SE, Dong H, Tamura H, et al. blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–6505. Epub 2003/10/16
  • Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;13:1129–1132.
  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. Epub 2015/06/02
  • Dang TO, Ogunniyi A, Barbee MS, et al. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16:13–20.
  • Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England). 2016;387:1837–1846. Epub 2016/03/14
  • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. Epub 2015/04/22.
  • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England). 2016;387:1540–1550. Epub 2015/12/30.
  • Lim SH, Sun JM, Lee SH, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2016;16:397–406.
  • Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823–1833. Epub 2016/10/11
  • Schouten RD, Muller M, Baas P, et al. Real life experience with Immunotherapy in the Netherlands Cancer Institute. Amsterdam: Elsevier. ABSTRACT, as presented at WCLC. 2016.
  • Vachhani P, Chen H. Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. Onco Targets Ther. 2016;9:5855–5866.
  • Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643–650.
  • Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015;22:953–958.
  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. Epub 2012/03/23.
  • Keir ME, Butte MJ, Freeman GJ. Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
  • Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
  • Kazandjian D, Suzman DL, Blumenthal G, et al. Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634–642.
  • Gettinger SN, Horn L, Gandhi L, et al. Overall survival and and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol: off J Am Soc Clin Oncol. 2015;33:2004–2012. Epub 2015/04/22.
  • Chatterjee M, Turner DC, Felip E, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol: off J Eur Soc Med Oncol. 2016;27:1291–1298.
  • Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–1508. Epub 2016/10/18
  • Carbognin L, Pilotto S, Milella M, et al. differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in Melanoma, lung and genitourinary cancers. Plos One. 2015;10:e0130142. Epub 2015/06/19
  • Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England). 2017;389:255–265.
  • Peters S, Antonia S, Goldberg SB, et al. 191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. J Thoracic Oncol off Publ Int Assoc Study Lung Cancer. 2016;11:S139–S140.
  • Planchard D, Yokoi T, McCleod MJ, et al. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer. 2016;17:232–236.e1.
  • Mok T, Schmid P, Aren O, et al. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. Journal of thoracic oncology. Off Publ Int Assoc Study Lung Cancer. 2016;11:S140–S141.
  • Jerusalem GCF, Spigel D, Iannotti N, et al. Javelin in solid tumor: safety and clinical activity of avelumab (anti-PD-L1) as first-line treatment in patients with advanced NSCLC. Amsterdam: Elsevier. ABSTRACT, as presented at WCLC. 2016.
  • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. Epub 2012/06/05
  • Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32–38.
  • Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res:Off J Am Assoc Cancer Res. 2015:21:4286–4293. Epub 2015/05/16.
  • Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer. 2015;3:36.
  • Ahamadi M, Freshwater T, Prohn M, et al. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):49-57.
  • Garon EB, Reck M, Rodriguez-Abreu D, et al. Use of a 200 mg fixed dose of pembrolizumab for the treatment of advanced non-small cell lung cancer (NSCLC). Amsterdam: Elsevier. ABSTRACT, as presented at WCLC. 2016.
  • Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014;384:1109–1117.
  • Vassiliki Papadimitrakopoulou AP, Borghaei H, Stevenson J, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy foradvanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. (Abstract only). Meet Library ASCO Annu Meet. J Clin Oncol 33, 2015 (suppl; abstr 8031).
  • Gubens LVS, Stevenson J, Powell SF, et al. Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. ABSTRACT, presented on 2016 ASCO Annual Meeting. J Clin Oncol 34, 2016 (suppl; abstr 9027).
  • Herbst G, Dong-Wan BC. Keynote-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed Pembrolizumab. Abstract, as presented at the WCLC december 2016 in Vienna.
  • Gadgeel S, Langer CJ, Gandhi L, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. J Clin Oncol. 2016;34(suppl; abstr 9016). ABSTRACT Presented as a poster at ASCO Annual meeting 2016.
  • Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res:Off J Am Assoc Cancer Res. 2009;15:7412–7420.
  • Herbst RSPB, Jose Luis P-G, Enriqueta F, et al. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. Amsterdam: Elsevier. J Clin Oncol. 2016;34(suppl; abstr 3030), ABSTRACT Presented as a poster at ASCO Annual meeting 2016.
  • Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol: off J Eur Soc Med Oncol. 2016;27:147–153. Epub 2015/10/21
  • Kim MY, Koh J, Kim S, et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015;88:24–33.
  • Mansfield AS, Aubry MC, Moser JC, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol: off J Eur Soc Med Oncol. 2016;27:1953–1958.
  • Costa R, Carneiro BA, Agulnik M, et al. Toxicity profile of approvedanti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Jan;6(1):49-57.
  • Brahmer JR. Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024 (ID 7213). Amsterdam: Elsevier. Abstract, as presented at the WCLC december 2016 in Vienna. 2016.
  • Summary of opinion on pembrolizumab. EMA Documents. EMA, London. 2016. [cited 2017 Mar 28] Available at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003820/WC500190993.pdf
  • Blank CU, Haanen JB, Ribas A, et al. CANCER IMMUNOLOGY. The “cancer immunogram”. Science (New York, NY). 2016;352:658–660. Epub 2016/05/07.
  • Sharyn Katz MH, Bagley S, Aggarwal C, et al. Imaging of Anti-PD1 therapy response in advanced non-small cell lung cancer. Amsterdam: Elsevier. Abstract, as presented at the WCLC december 2016 in Vienna. 2016.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.